David Grainger - Profile and Investment Details

Investor Profile

David Grainger is a Venture Capital based in Cambridge, England, United Kingdom with a diverse investment portfolio that includes companies such as Gadeta, SuperX, Critical Pressure, Impact Biomedicines, Inexia, Aura Biosciences, Janpix, Alderaan Biotechnology, ApcinteX, Yukin Therapeutics, Xenikos, Palladio Biosciences, Mavalon Therapeutics, Kymo Therapeutics, Sydnexis, Z Factor, Stealthyx Therapeutics, Pronostics Ltd, Checkmate Pharmaceuticals, Orexia, Vaxcyte, Morphogen-IX, Phathom Pharmaceuticals, Diasome Pharmaceuticals, Capella BioScience, Divide and Conquer, Synthorx, Breakpoint Therapeutics, . Over time, David Grainger has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether David Grainger is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Hospitals, Wellness, Women Founded, Biotechnology, Hispanic / Latinx Founded, Innovation, Clinical Trials, Research, Metabolic Health, Logistics, Medical, B2B, Therapeutics, App Discovery, Pharmaceuticals may find it worthwhile to explore potential connections with David Grainger, as their portfolio suggests a familiarity and interest in this area.

Understanding David Grainger’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.